Seeking Alpha12d
Sarepta plunges after death linked to Elevidys (update)
Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~20% on Tuesday to reach a new 52-week low after the company disclosed the death of a patient treated with Elevidys, its FDA-approved ...
FiercePharma13d
Sarepta reports one death after patient received DMD gene therapy Elevidys
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech said (PDF) Tuesday. The patient suffered ...
Monthly Prescribing Reference12d
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
The patient in this case had suffered acute liver failure following the Elevidys infusion. Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy (DMD) who received ...
Business Insider13d
Analysts remain optimistic about Elevidys after Sarepta reports patient death
Shares of Sarepta Therapeutics (SRPT) are under pressure on Tuesday after the company shared a safety update related to its Elevidys, the only approved gene therapy in patients with Duchenne ...
Healthline20d
Elevidys (delandistrogene moxeparvovec) Cost and Financial Assistance
The price you pay for Elevidys may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...
Seeking Alpha12d
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Sarepta Therapeutics stock dropped over 20% after a patient treated with Elevidys for DMD died from acute liver failure, raising safety concerns. Despite the incident, Sarepta maintains that the ...
Benzinga.com13d
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
Sarepta reported a patient death from acute liver failure after Elevidys treatment, though no new safety signal was identified. Over 800 patients have received Elevidys, and a recent CMV infection ...
Yahoo Finance13d
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
On Tuesday, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with ...
MedCity News12d
Liver Failure-Associated Death Reported in Patient Treated With Sarepta Gene Therapy Elevidys
A patient has died following treatment with Elevidys, the Sarepta Therapeutics product that is the only FDA-approved gene therapy for Duchenne muscular dystrophy, the company disclosed Tuesday.
Investing13d
Sarepta stock holds rating despite Elevidys death report
The news came following a disclosure that a 16-year-old patient who received the maximum dose of Elevidys experienced an acute liver injury and subsequently died. The patient also had a concurrent ...
Business Insider13d
BofA says Elevidys risk-reward favorable despite Sarepta report of patient death
After Sarepta (SRPT) reported the death of a Duchenne muscular dystrophy patient following treatment with Elevidys after suffering acute liver failure, BofA notes that acute liver failure is a ...
The Boston Globe12d
Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Sarepta Therapeutics said Tuesday that a 16-year-old boy died after receiving Elevidys, its gene therapy for Duchenne muscular dystrophy, the first known death linked to the treatment. The ...